kalydeco Drug Patent Profile

Which patents cover Kalydeco, and what generic alternatives are available?

Kalydeco is a drug marketed by Vertex Pharms Inc and Vertex Pharms and is included in two NDAs. There are fourteen patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and fifty-seven patent family members in thirty-six countries.

The generic ingredient in KALYDECO is ivacaftor. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ivacaftor profile page.

DrugPatentWatch^® Generic Entry Outlook for Kalydeco

Kalydeco was eligible for patent challenges on January 31, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 13, 2030. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (ivacaftor), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for kalydeco

International Patents:	257
US Patents:	14
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	94
Clinical Trials:	26
Patent Applications:	1,513
Drug Prices:	Drug price information for kalydeco
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for kalydeco
What excipients (inactive ingredients) are in kalydeco?	kalydeco excipients list
DailyMed Link:	kalydeco at DailyMed

See drug prices for kalydeco

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for kalydeco

Constraining patent/regulatory exclusivity:

8,883,206*PED

NDA:

207925

Dosage:

GRANULE;ORAL

Constraining patent/regulatory exclusivity:

10,646,481*PED

NDA:

203188

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for kalydeco

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2
University of Miami	Early Phase 1
University of Kansas Medical Center	Early Phase 1

See all kalydeco clinical trials

Pharmacology for kalydeco

Drug Class	Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
Mechanism of Action	Chloride Channel Activation Potentiators Cytochrome P450 2C9 Inhibitors Cytochrome P450 3A Inhibitors P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for KALYDECO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KALYDECO	Oral Granules	ivacaftor	25 mg, 50 mg and 75 mg	207925	1	2022-04-13
KALYDECO	Tablets	ivacaftor	150 mg	203188	1	2020-06-10

US Patents and Regulatory Information for kalydeco

kalydeco is protected by fourteen US patents and ten FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,646,481.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-001	Mar 17, 2015		RX	Yes	No	12,214,083*PED				Y
Vertex Pharms	KALYDECO	ivacaftor	TABLET;ORAL	203188-001	Jan 31, 2012		RX	Yes	Yes	7,495,103*PED				Y
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-003	Apr 29, 2019		RX	Yes	No	7,495,103*PED				Y

Expired US Patents for kalydeco

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-004	May 3, 2023	8,629,162
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-003	Apr 29, 2019	8,629,162
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-005	May 3, 2023	8,629,162

EU/EMA Drug Approvals for kalydeco

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Vertex Pharmaceuticals (Ireland) Limited	Kalydeco	ivacaftor	EMEA/H/C/002494Kalydeco tablets are indicated:As monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1).In a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the CFTR gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G, and 3849+10kbC→T.In a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who have at least one F508del mutation in the CFTR gene (see section 5.1).Kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1).	Authorised	no	no	no	2012-07-23

International Patents for kalydeco

When does loss-of-exclusivity occur for kalydeco?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

Montenegro

New Zealand

Norway

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering kalydeco around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	E032540
Mexico	2012001939
Cyprus	1118980

Supplementary Protection Certificates for kalydeco

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3170818	20C1037	France		PRODUCT NAME: LUMACAFTOR ET IVACAFTOR DANS TOUTES SES FORMES RELEVANT DE LA PROTECTION DU BREVET DE BASE; REGISTRATION NO/DATE: EU/1/15/1059 20151124
1773816	C01773816/01	Switzerland		PRODUCT NAME: IVACAFTOR; REGISTRATION NO/DATE: SWISSMEDIC 62686 13.01.2014
1773816	2015/036	Ireland		PRODUCT NAME: N-(5-HYDROXYL-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE (IVACAFTOR) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120723

Kalydeco: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Kalydeco (ivacaftor) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator approved for treating specific mutations in cystic fibrosis (CF) patients. Its market performance is directly tied to the prevalence of these identified mutations and the drug's efficacy in improving lung function and clinical outcomes. Financial projections are influenced by patent exclusivity, competition from other CF therapies, and pricing strategies.

What is Kalydeco and How Does it Function?

Kalydeco is a small molecule drug developed by Vertex Pharmaceuticals. It targets the underlying cause of cystic fibrosis by increasing the flow of chloride ions across the cell membrane in patients with specific CFTR gene mutations. The drug binds to the defective CFTR protein and helps it to open, allowing for the passage of chloride ions. This action corrects the ion transport defect in CF cells, leading to improved hydration of airway surfaces and reduced mucus accumulation.

Kalydeco is indicated for the treatment of CF in patients aged 6 months and older who possess at least one mutation in the CFTR gene for which ivacaftor is effective. The U.S. Food and Drug Administration (FDA) initially approved Kalydeco in 2012 for individuals with the G551D mutation. Subsequent approvals have expanded its use to include other rare gating mutations.

What are the Key CFTR Mutations Treated by Kalydeco?

The efficacy of Kalydeco is specific to certain CFTR mutations. These are primarily gating mutations, where the CFTR protein is produced but does not open correctly. As of the latest regulatory approvals, Kalydeco is indicated for:

• G551D mutation: This was the first mutation for which Kalydeco received approval. It is a gating mutation.
• Other gating mutations: The FDA has expanded Kalydeco's label to include other rare gating mutations, such as G1349D, G1784A, G551S, G1244E, S549I, S549R, and G1349D, among others.

The presence of at least one copy of these specific mutations is a prerequisite for Kalydeco treatment. This necessitates genetic testing for CF patients to determine eligibility.

What is the Market Size and Patient Population for Kalydeco?

The market size for Kalydeco is defined by the prevalence of CF patients with the specific mutations it treats. Cystic fibrosis affects approximately 30,000 individuals in the United States and around 70,000 worldwide [1]. The proportion of these patients with gating mutations responsive to Kalydeco is a subset of the overall CF population.

Historically, the G551D mutation was estimated to affect around 4% of CF patients with at least one identified mutation in the U.S. [2]. The expansion of Kalydeco's label to include other rare gating mutations has increased the eligible patient pool, though these mutations are individually less common.

The global market for CFTR modulators, including Kalydeco, has seen significant growth driven by an expanding approved patient population and increased diagnosis rates. While specific market figures for Kalydeco alone are often consolidated within Vertex's broader CF portfolio, the company reported total CF product revenues of $8.95 billion in 2022, with Kalydeco being a foundational product in this portfolio [3]. The addressable market is further influenced by patient access, healthcare reimbursement policies, and the availability of alternative treatments.

What is the Competitive Landscape for Kalydeco?

The competitive landscape for Kalydeco is characterized by other CFTR modulators, primarily developed by Vertex Pharmaceuticals. These include:

• Orkambi (lumacaftor/ivacaftor): Approved for patients with two copies of the F508del mutation.
• Symdeko (tezacaftor/ivacaftor): Approved for patients aged 12 years and older with two copies of the F508del mutation or one copy of the F508del mutation and one mutation that results in residual function.
• Trikafta (elexacaftor/tezacaftor/ivacaftor): A triple combination therapy approved for patients aged 12 years and older with at least one copy of the F508del mutation.

Comparison of Vertex CFTR Modulators:

Product Name	Active Ingredients	Approved Mutations	Target Patient Population (Age)	Status
Kalydeco (ivacaftor)	Ivacaftor	Gating mutations (e.g., G551D, G1349D, G1784A, G551S, G1244E, S549I, S549R)	6 months and older	Monotherapy
Orkambi (lumacaftor/ivacaftor)	Lumacaftor, Ivacaftor	Two copies of F508del mutation	2 years and older	Dual combination therapy
Symdeko (tezacaftor/ivacaftor)	Tezacaftor, Ivacaftor	Two copies of F508del mutation, or one F508del and one residual function mutation	12 years and older	Dual combination therapy
Symkevi (tezacaftor/ivacaftor) (EU equivalent)	Tezacaftor, Ivacaftor	Two copies of F508del mutation, or one F508del and one residual function mutation	12 years and older	Dual combination therapy
Kaftrio (elexacaftor/ivacaftor/tezacaftor) (EU)	Elexacaftor, Ivacaftor, Tezacaftor	At least one copy of the F508del mutation	12 years and older	Triple combination therapy
Trikafta (elexacaftor/tezacaftor/ivacaftor)	Elexacaftor, Tezacaftor, Ivacaftor	At least one copy of the F508del mutation	12 years and older	Triple combination therapy. Significant market share gain from Kalydeco.

Trikafta, a triple-combination therapy, has become the standard of care for a larger patient population and has consequently impacted the market share for earlier-generation therapies like Kalydeco, particularly in patients with the F508del mutation. Kalydeco remains crucial for patients with specific gating mutations who do not have the F508del mutation. The competitive landscape is thus segmented by the specific genetic mutations present in CF patients.

What is the Patent Exclusivity Status for Kalydeco?

Kalydeco has been subject to patent protections and subsequent market exclusivity. The initial U.S. patent for ivacaftor and its use in treating CF was filed in the early 2000s. Key patents related to Kalydeco have expiration dates that vary by region and patent family.

U.S. patent protection for the core composition of matter and methods of use has been extended, but the drug is approaching or has faced patent expiries in certain markets. For example, primary U.S. patents for ivacaftor began expiring around 2020-2022. However, Vertex Pharmaceuticals has pursued further patent filings for improved formulations, delivery methods, and combination therapies that can extend market exclusivity.

The development of combination therapies like Trikafta, which includes ivacaftor, creates a new generation of intellectual property. While Kalydeco as a monotherapy faces generic competition as its primary patents expire, its active ingredient, ivacaftor, continues to be protected as a component of newer, patented combination drugs. This strategy has allowed Vertex to maintain market dominance in the CF space.

Projected Patent Expirations and Market Impact:

• Core Ivacaftor Patents: Many have expired or are set to expire in major markets (U.S., EU) between 2020 and 2025.
• Formulation/Method of Use Patents: Additional patents may provide a buffer, extending exclusivity for specific uses or formulations.
• Combination Therapy Patents: Patents covering Trikafta and similar therapies (containing ivacaftor) offer protection for newer products, but do not directly extend Kalydeco monotherapy exclusivity.

The emergence of generic ivacaftor for monotherapy use in eligible patients is a direct consequence of patent expiry. This typically leads to price reductions and potential shifts in market share.

What are the Financial Performance and Revenue Drivers for Kalydeco?

Kalydeco has been a significant revenue generator for Vertex Pharmaceuticals since its approval. Its financial performance is driven by several factors:

• High Unmet Need: CF is a serious genetic disease with limited treatment options prior to CFTR modulators.
• Efficacy and Clinical Benefits: Kalydeco demonstrated significant improvements in lung function (FEV1), reduced exacerbations, and improved quality of life for eligible patients.
• Orphan Drug Status: In many regions, Kalydeco benefited from orphan drug designations, which provide market exclusivity and other incentives.
• Pricing: As a therapy addressing a rare disease with a high burden of care and significant clinical benefit, Kalydeco commanded premium pricing.

Revenue Trend Analysis (Vertex Pharmaceuticals CF Portfolio):

Year	Total CF Product Revenue (USD Billions)
2019	4.81
2020	6.21
2021	7.58
2022	8.95
2023 (Q3 YTD)	7.25

Note: This table reflects the combined revenue of all Vertex CF products. Kalydeco's specific contribution diminishes as newer therapies gain market share.

While Kalydeco was a foundational product, its revenue contribution has been increasingly overshadowed by the success of combination therapies like Trikafta. Trikafta, with its broader indication covering approximately 90% of CF patients, has driven substantial revenue growth. Kalydeco's revenue is now primarily derived from the specific niche of patients with gating mutations not amenable to triple therapy. Nonetheless, it remains a profitable product due to its established patient base and the continued high cost of CF treatments.

What are the Future Market Projections for Kalydeco?

The future market projections for Kalydeco are nuanced. As a monotherapy, its market share is expected to decline gradually due to:

• Patent Expirations and Generic Entry: The introduction of generic ivacaftor will likely lead to price erosion and reduced revenue for Vertex's branded Kalydeco.
• Competition from Triple Therapies: Trikafta and similar next-generation therapies are becoming the standard of care for an increasing proportion of CF patients, displacing the need for Kalydeco in many instances.

However, Kalydeco will likely maintain a significant role in:

• Specific Patient Niches: Patients with rare gating mutations who are not candidates for triple therapy will continue to rely on Kalydeco.
• Developing Markets: In regions with slower adoption of newer, more expensive therapies, Kalydeco may retain a larger market presence for longer.
• Component of Combination Therapies: The active pharmaceutical ingredient, ivacaftor, remains critical in combination therapies, ensuring its continued relevance and revenue generation as part of these products.

Vertex Pharmaceuticals has focused its R&D efforts on developing therapies for the remaining CF patient population not served by current modulators and on optimizing existing treatments. The company's strategy involves lifecycle management and expanding the utility of its CF pipeline. For Kalydeco specifically, future revenue will be largely determined by the size of its remaining niche patient population, the pricing of generic alternatives, and its integration into future therapeutic strategies.

What are the Regulatory and Reimbursement Considerations?

Kalydeco's market access and financial trajectory are heavily influenced by regulatory approvals and reimbursement policies.

Regulatory Landscape:

• FDA and EMA Approvals: Kalydeco has received approvals from major regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific indications based on identified CFTR mutations.
• Label Expansions: Vertex has actively sought and achieved label expansions for Kalydeco to include a wider range of gating mutations, thereby increasing the eligible patient population.
• Post-Market Surveillance: Ongoing monitoring of safety and efficacy data is a standard requirement, which can influence prescribing patterns and regulatory standing.

Reimbursement Landscape:

• High Cost of Treatment: CFTR modulators are among the most expensive drugs on the market, necessitating robust reimbursement strategies.
• Payer Negotiations: Pharmaceutical companies engage in complex negotiations with private insurers and government healthcare programs (e.g., Medicare, Medicaid) to secure formulary placement and favorable reimbursement rates.
• Value-Based Pricing: In some markets, discussions around value-based agreements are increasing, where reimbursement is tied to demonstrated patient outcomes. Kalydeco's clear clinical benefits have historically supported its pricing and reimbursement.
• Generic Pricing Pressures: Upon patent expiry, payers often exert pressure to lower prices or favor generic alternatives, which will impact Kalydeco's revenue.
• International Variations: Reimbursement policies vary significantly across different countries, affecting global market access and revenue generation.

The ability to demonstrate significant clinical utility and cost-effectiveness against the backdrop of the disease's burden has been critical for Kalydeco's reimbursement. However, the emergence of newer, more comprehensive therapies introduces new benchmarks for value assessment.

Key Takeaways

• Kalydeco (ivacaftor) is a CFTR potentiator targeting specific gating mutations in cystic fibrosis.
• Its market success is directly tied to the prevalence of these rare mutations and its demonstrated clinical efficacy.
• The competitive landscape is dominated by Vertex Pharmaceuticals' own advanced CFTR modulator therapies, particularly the triple combination Trikafta.
• While core patents for Kalydeco have expired or are expiring, ivacaftor remains a key component in newer, patented combination drugs.
• Kalydeco's financial performance has been robust, driven by high unmet need, clinical benefit, and premium pricing, though its individual revenue contribution is declining relative to newer therapies.
• Future projections indicate a shrinking but stable niche market for Kalydeco monotherapy, alongside continued revenue as part of combination treatments.
• Regulatory approvals and evolving reimbursement policies significantly shape Kalydeco's market access and financial trajectory.

Frequently Asked Questions

1. What is the primary reason for Kalydeco's declining market share as a monotherapy? The primary reason is the development and market dominance of triple-combination CFTR modulators like Trikafta, which address a much larger percentage of the CF patient population, including those with the F508del mutation.

2. Will generic versions of Kalydeco be available, and what impact will they have? Yes, as key patents expire, generic versions of ivacaftor are becoming available. This will likely lead to significant price reductions for the monotherapy indication and a decrease in branded Kalydeco revenue for Vertex Pharmaceuticals.

3. What is the current role of Kalydeco in the treatment of cystic fibrosis? Kalydeco's current role is primarily for patients who have specific gating mutations in the CFTR gene and are not candidates for or do not benefit sufficiently from triple-combination therapies. It remains a critical treatment for this specific patient subset.

4. How does Kalydeco's efficacy compare to newer CFTR modulators? Kalydeco monotherapy demonstrates significant improvements in lung function for patients with specific gating mutations. However, newer combination therapies like Trikafta offer more comprehensive restoration of CFTR function and are thus more effective for a broader range of mutations, including those with the F508del mutation.

5. What are the key mutations that Kalydeco is still the primary treatment for? Kalydeco is the primary treatment for patients with specific rare gating mutations, such as G551D, G1349D, G1784A, G551S, G1244E, S549I, and S549R, when these are present and no other modulator therapy is indicated or preferred.

Citations

[1] Cystic Fibrosis Foundation. (n.d.). About Cystic Fibrosis. Retrieved from https://www.cff.org/about-cystic-fibrosis

[2] U.S. Food and Drug Administration. (2012, January 31). FDA approves Kalydeco (ivacaftor) for cystic fibrosis patients with the G551D mutation. [Press Release].

[3] Vertex Pharmaceuticals. (2023). Vertex Pharmaceuticals Incorporated 2022 Annual Report. Retrieved from https://investors.vrtx.com/financial-reporting/annual-reports